大脑免疫细胞中的蛋白质可能加速阿尔茨海默病的损害
A protein in the brain's immune cells may accelerate damage in Alzheimer's disease
瑞典隆德大学的研究发现,蛋白质 galectin-3 在阿尔茨海默病中不仅影响大脑免疫细胞的反应,还重塑淀粉样斑块,可能加剧神经损伤。研究显示 galectin-3 可能成为未来治疗靶点,但其对患者的具体益处仍需临床试验验证。
Researchers at Lund University in Sweden have identified a key role for the protein galectin-3 in Alzheimer's disease. The study shows that galectin-3 not only influences how the brain's immune cells, known as microglia, react to the disease's characteristic amyloid plaques but also shapes the plaques themselves—and may contribute to the nerve damage that develops around them.
"This discovery provides new insights into the mechanisms of the disease and identifies galectin-3 as a potential future therapeutic target," says Lluís Camprubí-Ferrer, one of the study's lead authors and a postdoctoral researcher at Lund University.
The study is published in the journal Proceedings of the National Academy of Sciences.
Galectin-3 actively reshapes amyloid plaques
Alzheimer's disease (AD) is characterized by accumulations of beta-amyloid (Aβ) in the brain. These proteins clump together to form plaques. In a previous study, the research team at Lund University showed for the first time that the protein galectin-3 increases in the brains of people with Alzheimer's disease and that removing the protein decreased inflammation in the brain. In this new study, the researchers have shown the direct relationship between galectin-3 and Aβ plaques.
The new study shows that galectin-3 binds "with remarkable strength" to Aβ and that it acts in two places at once. Outside the microglia, it sits on the plaque itself, where it changes the shape of the amyloid fibers as they grow. Inside the microglia, it sits in the lysosomes (the compartments where the cell breaks down what it has swallowed), where it steers how amyloid is processed. Galectin-3, the researchers conclude, is not merely present around the plaque: It actively shapes it.
"No one has previously shown what galectin-3 does to the plaque itself. We have observed that the protein binds to long protein strands known as amyloid fibrils, blocking one of the steps by which they multiply and altering their shape. In cell experiments, the fibrils reshaped by galectin-3 went on to damage nerve cells," explains Camprubí-Ferrer.
Removing galectin-3 limits damage in mice
The current study was carried out on both mice and human tissue, in collaboration with the University of Seville and the Instituto de Biomedicina de Sevilla (IBiS) in Spain. When the researchers removed galectin-3 in mice with an Alzheimer's-like disease, the plaques became smaller and more tightly packed. The surrounding nerve endings were damaged to a significantly lesser extent, and the immune cells (microglia) shifted from an aggressive, inflammatory state to a protective one.
"When we inactivated galectin-3, microglia transitioned from their harmful state to a state rich in the protective receptor TREM2, a protein that we know plays an important role in the brain's immune defense and in the risk of Alzheimer's disease," says Camprubí-Ferrer.
Patient benefits remain to be tested
The results of the animal studies are clear-cut, showing a cause-and-effect relationship. The experiments on human tissue, from nine individuals, show a strong correlation. What the researchers cannot yet say is whether blocking galectin-3 helps patients. Only a clinical trial can provide an answer to that.
"This is important because current Alzheimer's drugs target amyloid without helping to reduce inflammation in the brain. And galectin-3 is a protein that drugs can actually bind to," says Camprubí-Ferrer.
"And the timing is right. Drugs containing antibodies that break down amyloid have reached patients, but their modest effect has drawn attention to the brain's immune response. That is where we can now fill in the gaps," says Tomas Deierborg, professor and leader of the Experimental Neuroinflammation research group at Lund University.
Deierborg finds it particularly encouraging that their early discoveries have now led to clinical trials. Just a few weeks ago, U.S. regulators gave the go-ahead for a phase 2 trial of an antibody that blocks galectin-3.
"This demonstrates the clinical potential of our research findings," says Deierborg.
Publication details
Lluís Camprubí-Ferrer et al., Galectin-3 links microglial neuroinflammation to Aβ aggregation and lysosomal processing, Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2625362123
Journal information: Proceedings of the National Academy of Sciences
Clinical categories
Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: A protein in the brain's immune cells may accelerate damage in Alzheimer's disease (2026, November 20) retrieved 20 November 2026 from https://medicalxpress.com/news/2026-11-protein-brain-immune-cells-alzheimer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com